Virta Health
Virta Health sells a remote, nutrition-first treatment for type 2 diabetes, obesity and other metabolic diseases. It sells to employers, health plans and PBMs.
Virta delivers a continuous remote-care treatment that combines personalized nutrition therapy, AI and data tools, physician oversight and human health coaching. The aim is to reverse type 2 diabetes and reduce reliance on medications such as insulin. It sells mainly B2B to large employers, payers and pharmacy benefit managers, often on performance-based contracts tied to outcomes and cost savings. In June 2026 it expanded GLP-1 medication fulfillment options for employers. Its last major round was a $133M Series E in 2021 at a $2B valuation, and total funding is reported at roughly $370M–$400M depending on the source.
